Theravance Biopharma (TBPH) Restructuring Costs (2021 - 2026)

Theravance Biopharma (TBPH) has 4 years of Restructuring Costs data on file, last reported at $2.6 million in Q1 2026.

• On a quarterly basis, Restructuring Costs changed N/A year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was $3.8 million, a N/A change from a year earlier, with the FY2023 full-year figure at $2.7 million, down 78.57% from the prior year.
• Restructuring Costs for Q1 2026 stood at $2.6 million, up from $1.2 million in the prior quarter.
• Over the last five years, Restructuring Costs for TBPH reached as high as $33.0 million in Q3 2022 and fell as low as -$38000.0 in Q4 2022.
• Historically, Restructuring Costs has averaged $11.9 million across 3 years, with a median of $2.6 million in 2026.
• On a YoY basis, Restructuring Costs climbed as much as 114.29% in 2022 and fell as far as 100.21% in 2022.
• Year by year, Restructuring Costs stood at -$38000.0 in 2022, then jumped by 3176.32% to $1.2 million in 2023, then soared by 122.84% to $2.6 million in 2026.
• Per Business Quant data, the three most recent Restructuring Costs figures were $2.6 million in Q1 2026, $1.2 million in Q2 2023, and $1.6 million in Q1 2023.